Yazar "Spelman, T." için listeleme

Toplam kayıt 23, listelenen: 1-20

10-year progression predictors after first treatment initiation in a relapsing-remitting MS cohort

Jokubaitis, V. G.; Spelman, T.; Kalincik, T.; Travaglini, D.; Paolicelli, D.; Duquette, P.; Verheul, F. (Sage Publications Ltd, 2015)

…
Anti-inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosis

Lorscheider, J.; Jokubaitis, V.; Spelman, T.; Izquierdo, G.; Lugaresi, A.; Havrdova, E.; Ramo-Tello, C. (Sage Publications Ltd, 2016)

…
Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis

Kalincik, T.; Jokubaitis, V.; Spelman, T.; Horakova, D.; Havrdova, E.; Trojano, M.; Barnett, M. (Sage Publications Ltd, 2017)

…
Comparative analysis of MS outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide

Spelman, T.; Kalincik, T.; Trojano, M.; Grand'Maison, F.; Izquierdo, G.; Havrdova, E.; Butzkueven, H. (Sage Publications Ltd, 2016)

…
Comparative analysis of MS outcomes in natalizumab-treated patients using a novel three-way multinomial propensity score match

Spelman, T.; Pellegrini, F.; Zhang, A.; Trojano, M.; Wiendl, H.; Kappos, L.; Butzkueven, H. (Sage Publications Ltd, 2016)

…
Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry.

Spelman, T.; Harvrdova, E. K.; Horakova, D.; Izquierdo, G.; Kalincik, T.; Lugaresi, A.; McCombe, P. (Sage Publications Ltd, 2018)

…
Comparative efficacy of first-line natalizumab versus IFNb or glatiramer acetate in relapsing MS

Spelman, T.; Kalincik, T.; Jokubaitis, V.; Zhang, A.; Pellegrini, F.; Wiendl, H.; Lechner-Scott, J. (Sage Publications Ltd, 2015)

…
Comparative efficacy of switch to natalizumab or fingolimod in active relapsing-remitting multiple sclerosis

Kalincik, T.; Horakova, D.; Spelman, T.; Jokubaitis, V.; Trojano, M.; Lugaresi, A.; Bergamaschi, R. (Sage Publications Ltd, 2014)

…
A comparative-effectiveness analysis applying a 3 way propensity matching to real-world data from MSBase Registry in preparation for a cost effectiveness model: patients switching within firstline agents or to natalizumab or fingolimod in active RRMS

Spelman, T.; Havrdova, E.; Horakova, D.; Trojano, M.; Lugaresi, A.; Izquierdo, G.; Butzkueven, H. (Sage Publications Ltd, 2017)

…
Comparison of efficacy and persistence of first line fingolimod vs interferon-beta/glatiramer in the presence of prior disease activity

Spelman, T.; Izquierdo, G.; Alroughani, R.; Fernandez Bolaos, R.; Havrdova, E.; Horaova, D.; Butzkueven, H. (Sage Publications Ltd, 2015)

…
Contribution of inflammation to disability accrual in primary progressive multiple sclerosis

Hughes, J.; Jokubaitis, V.; Spelman, T.; Lugaresi, A.; Hupperts, R.; Izquierdo, G.; Granella, F. (Sage Publications Ltd, 2017)

…
Defining secondary progressive multiple sclerosis

Lorscheider, J.; Buzzard, K.; Jokubaitis, V.; Spelman, T.; Havrdova, E.; Horakova, D.; Van Pesch, V. (Sage Publications Ltd, 2015)

…
Disease modifying therapy improves disability outcomes in relapsing-remitting multiple sclerosis over 22 years

Kalincik, T.; Spelman, T.; Jokubaitis, V.; Horakova, D.; Havrdova, E.; Trojano, M.; Pucci, E. (Sage Publications Ltd, 2017)

…
Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study

Kalincik, T.; Spelman, T.; Jokubaitis, V.; Horakova, D.; Havrdova, E.; Izquierdo, G.; McCombe, P. (Sage Publications Ltd, 2017)

…
Efficacy and Treatment Persistence of First-line Natalizumab vs. Interferon beta or Glatiramer Acetate in relapsing MS.

Butzkueven, H.; Spelman, T.; Kalincik, T.; Jokubaitis, V.; Zhang, A.; Pellegrini, F.; La Spitaleri, D. (Sage Publications Ltd, 2016)

…
Evaluation of common criteria of progression of disability in a large observational cohort

Kalincik, T.; Jokubaitis, V.; Spelman, T.; Horakova, D.; Havrdova, E.; Trojano, M.; Terzi, M. (Sage Publications Ltd, 2014)

…
Halting disability progression in multiple sclerosis with immunomodulatory injectable treatments: Is it achievable?

Fragoso, Y. D.; Spelman, T.; Duquette, P.; Girard, M.; Trojano, M.; Izquierdo, G.; Butzkueven, H. (Sage Publications Ltd, 2017)

…
Independent predictors of time to relapse after CIS in high-risk patients

Spelman, T.; Meyniel, C.; Trojano, M.; Lugaresi, A.; Izquierdo, G.; Grand'Maison, F.; Butzkueven, H. (Sage Publications Ltd, 2014)

…
Individual response to disease modifying therapies: a global observational cohort study

Kalincik, T.; Sobisek, L.; Jokubaitis, V.; Spelman, T.; Horakova, D.; Havrdova, E.; Granella, F. (Sage Publications Ltd, 2016)

…
Predictors of relapses and disability progression after stopping disease-modifying therapies for multiple sclerosis

Kister, I.; Spelman, T.; Patti, F.; Duquette, P.; Trojano, M.; Izquierdo, G.; Butzkueven, H. (Sage Publications Ltd, 2017)

…